Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

732.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 77
Open 732.20
Bid (Size) 725.00 (2)
Ask (Size) 729.99 (1)
Prev. Close 732.20
Today's Range 732.20 - 732.20
52wk Range 370.68 - 800.78
Shares Outstanding N/A
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
Explore the dynamics of money-maker stocks in 2024, which are fueled by AI advancements and robust economic growth. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga

Performance

YTD
+23.64%
+23.64%
1 Month
-5.30%
-5.30%
3 Month
+15.54%
+15.54%
6 Month
+24.85%
+24.85%
1 Year
+90.26%
+90.26%

More News

Read More
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
SPDR ETF Report For Friday, April 19
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Via InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.